Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy.
作者信息
Raychaudhuri Suravi, Othus Megan, Percival Mary-Elizabeth M, Garcia-Manero Guillermo, Appelbaum Frederick R, Erba Harry P, Appelbaum Jacob S
机构信息
Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA.
Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA.
出版信息
Blood Neoplasia. 2025 Jun 14;2(3):100129. doi: 10.1016/j.bneo.2025.100129. eCollection 2025 Aug.
Abstract
摘要
相似文献
1
Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapy.接受强化化疗的急性髓系白血病患者因毒性而停药。
Blood Neoplasia. 2025 Jun 14;2(3):100129. doi: 10.1016/j.bneo.2025.100129. eCollection 2025 Aug.
2
Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.不适合标准诱导化疗的急性髓细胞白血病患者的治疗方法：系统评价。
Future Oncol. 2023 Apr;19(11):789-810. doi: 10.2217/fon-2022-1286. Epub 2023 May 12.
3
Efficacy of non-intensive therapies approved for relapsed/refractory acute myeloid leukemia: a systematic literature review.获批用于复发/难治性急性髓系白血病的非强化疗法的疗效：一项系统文献综述
Future Oncol. 2022 May;18(16):2029-2039. doi: 10.2217/fon-2021-1355. Epub 2022 Feb 24.
4
A systematic overview of chemotherapy effects in acute myeloid leukaemia.急性髓系白血病化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):231-52. doi: 10.1080/02841860151116321.
5
Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association.接受新型靶向治疗的成年急性髓系白血病患者的抗真菌预防：欧洲血液学协会的系统评价和专家共识推荐
Lancet Haematol. 2022 May;9(5):e361-e373. doi: 10.1016/S2352-3026(22)00073-4.
6
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial.沃多替尼用于对多线既往治疗耐药或不耐受的费城染色体阳性慢性髓性白血病患者：一项开放标签、多中心、1/2期试验。
Lancet Haematol. 2025 Mar;12(3):e201-e213. doi: 10.1016/S2352-3026(24)00354-5. Epub 2025 Feb 7.
7
REGAL: galinpepimut-S vs. best available therapy as maintenance therapy for acute myeloid leukemia in second remission.REGAL研究：galinpepimut-S与最佳可用疗法作为急性髓系白血病第二次缓解期维持治疗的比较。
Future Oncol. 2025 Jan;21(1):73-81. doi: 10.1080/14796694.2024.2433935. Epub 2024 Nov 28.
8
Discontinuation risk from adverse events: immunotherapy alone vs. combined with chemotherapy: a systematic review and network meta-analysis.停药风险与不良事件：免疫治疗与联合化疗的对比：系统评价和网络荟萃分析。
BMC Cancer. 2024 Jan 30;24(1):152. doi: 10.1186/s12885-024-11897-4.
9
Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support.对于接受强化化疗或放疗或两者联合治疗、有或没有造血干细胞支持的血液系统恶性肿瘤患者，采用限制性与宽松性红细胞输血策略的比较。
Cochrane Database Syst Rev. 2017 Jan 27;1(1):CD011305. doi: 10.1002/14651858.CD011305.pub2.
10
Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis.维奈托克联合低剂量阿糖胞苷或去甲基化药物作为不适合强化化疗的未经治疗的急性髓系白血病患者的诱导化疗：系统评价和荟萃分析。
Clin Exp Med. 2023 Jun;23(2):219-227. doi: 10.1007/s10238-021-00784-y. Epub 2022 Jan 23.
本文引用的文献
1
Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML.维奈托克与地西他滨对比强化化疗用于新诊断急性髓系白血病年轻患者的诱导治疗
Blood. 2025 May 29;145(22):2645-2655. doi: 10.1182/blood.2024027217.
2
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.一项关于标准剂量与高剂量阿糖胞苷联合或不联合伏立诺他治疗急性髓系白血病的随机III期研究。
Leukemia. 2024 Jan;38(1):58-66. doi: 10.1038/s41375-023-02073-x. Epub 2023 Nov 7.
3
Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial.低级别和中级别不良事件对患者治疗体验和治疗中断的重要性：E1912 试验分析。
J Clin Oncol. 2024 Jan 20;42(3):266-272. doi: 10.1200/JCO.23.00377. Epub 2023 Oct 6.
4
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.ELEVATE-RR 试验中，阿卡替尼与伊布替尼治疗复发/难治性慢性淋巴细胞白血病的详细安全性比较。
Blood. 2023 Aug 24;142(8):687-699. doi: 10.1182/blood.2022018818.
5
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.成人 AML 的诊断与治疗：ELN 专家组代表发布的 2022 年国际专家建议
Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867.
6
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.维奈托克联合 FLAG-IDA 诱导和巩固治疗新诊断的急性髓系白血病。
Am J Hematol. 2022 Aug;97(8):1035-1043. doi: 10.1002/ajh.26601. Epub 2022 May 30.
7
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.维奈托克联合 FLAG-IDA 诱导和巩固治疗新诊断和复发/难治性急性髓系白血病。
J Clin Oncol. 2021 Sep 1;39(25):2768-2778. doi: 10.1200/JCO.20.03736. Epub 2021 May 27.
8
Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203.预测成人急性髓系白血病强化诱导化疗的严重毒性：SWOG癌症研究网络试验S0106和S1203的分析
Leuk Lymphoma. 2021 Jul;62(7):1774-1777. doi: 10.1080/10428194.2021.1881512. Epub 2021 Feb 9.
9
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.针对复发/难治性急性髓系白血病及其他高级别髓系肿瘤，进行克拉屈滨、大剂量阿糖胞苷、米托蒽醌和粒细胞集落刺激因子联合剂量递增米托蒽醌的I/II期试验。
Haematologica. 2019 Apr;104(4):e143-e146. doi: 10.3324/haematol.2018.204792. Epub 2018 Nov 8.
10
Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.GCLAM 联合剂量递增米托蒽醌治疗初诊 AML 或其他高级别髓系肿瘤的 1/2 期临床试验。
Leukemia. 2018 Nov;32(11):2352-2362. doi: 10.1038/s41375-018-0135-8. Epub 2018 Apr 17.
Zotero 插件